MX383685B - Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. - Google Patents

Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.

Info

Publication number
MX383685B
MX383685B MX2017014471A MX2017014471A MX383685B MX 383685 B MX383685 B MX 383685B MX 2017014471 A MX2017014471 A MX 2017014471A MX 2017014471 A MX2017014471 A MX 2017014471A MX 383685 B MX383685 B MX 383685B
Authority
MX
Mexico
Prior art keywords
clonidine
radiotherapy
prevention
skin injury
derivatives
Prior art date
Application number
MX2017014471A
Other languages
English (en)
Other versions
MX2017014471A (es
Inventor
Bérangère Vasseur-Demarcy
Pierre Attali
Original Assignee
Monopar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc filed Critical Monopar Therapeutics Inc
Publication of MX2017014471A publication Critical patent/MX2017014471A/es
Publication of MX383685B publication Critical patent/MX383685B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/08—Dichloro-benzenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención concierne a una composición farmacéutica que comprende un portador farmacéuticamente aceptable y Clonidina o derivados de Clonidina como un único ingrediente activo para uso en la prevención de lesión de la piel resultante de la radioterapia por administración transmucosa.
MX2017014471A 2015-05-13 2016-05-10 Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. MX383685B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305728 2015-05-13
PCT/EP2016/060466 WO2016180834A1 (en) 2015-05-13 2016-05-10 Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy

Publications (2)

Publication Number Publication Date
MX2017014471A MX2017014471A (es) 2018-06-11
MX383685B true MX383685B (es) 2025-03-14

Family

ID=53199907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014471A MX383685B (es) 2015-05-13 2016-05-10 Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.

Country Status (13)

Country Link
US (1) US11090290B2 (es)
EP (1) EP3294292A1 (es)
JP (1) JP7102147B2 (es)
KR (1) KR20180004784A (es)
CN (1) CN107708691A (es)
AU (1) AU2016260785B2 (es)
BR (1) BR112017024356A2 (es)
CA (1) CA2985689A1 (es)
HK (1) HK1251178A1 (es)
IL (1) IL255544B (es)
MX (1) MX383685B (es)
WO (1) WO2016180834A1 (es)
ZA (1) ZA201707603B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
FR2665357B1 (fr) 1990-07-31 1995-03-31 Aiache Jean Marc Procede de preparation d'une forme galenique bio-adhesive et forme galenique ainsi preparee.
WO2002045717A1 (en) * 2000-12-06 2002-06-13 Tularik Inc. Lometrexol combination therapy
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
FR2889417B1 (fr) 2005-08-05 2008-02-08 Roquette Freres Proteines de pois texturee
EP1972332A1 (en) 2007-03-23 2008-09-24 BioAlliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
EP2165706A1 (en) * 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
EP2368549A1 (en) * 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
CA2841632A1 (en) * 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
WO2014018571A2 (en) * 2012-07-25 2014-01-30 Sova Pharmaceuticals, Inc. Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders

Also Published As

Publication number Publication date
BR112017024356A2 (pt) 2018-07-31
JP7102147B2 (ja) 2022-07-19
WO2016180834A1 (en) 2016-11-17
KR20180004784A (ko) 2018-01-12
JP2018519271A (ja) 2018-07-19
CN107708691A (zh) 2018-02-16
MX2017014471A (es) 2018-06-11
CA2985689A1 (en) 2016-11-17
HK1251178A1 (zh) 2019-01-25
ZA201707603B (en) 2019-05-29
US11090290B2 (en) 2021-08-17
EP3294292A1 (en) 2018-03-21
AU2016260785A1 (en) 2017-11-30
AU2016260785B2 (en) 2022-06-02
IL255544A (en) 2018-01-31
IL255544B (en) 2020-09-30
US20180098967A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
CL2020000747A1 (es) Formulaciones de niraparib.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
MX383685B (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
MX378376B (es) Composicion farmaceutica para el tratamiento de la micosis.